MAP2K7 and Histiocytosis: Given these results, the BRAF inhibitor dabrafenib, the MAPK kinase (MEK) inhibitors cobimetinib and trametinib, and various combinations of BRAF and MEK inhibitors were administered to patients with histiocytosis, with similar results.18